Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 26,768,604 | 20,421,917 | 30,012,027 | 21,442,951 | 18,613,419 | 117,258,918 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 26,768,604 | 20,421,917 | 30,012,027 | 21,442,951 | 18,613,419 | 117,258,918 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 4,002,103 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 113,256,815 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 26,768,604 | 20,421,917 | 30,012,027 | 21,442,951 | 18,613,419 | 117,258,918 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 1,482,196 | 1,373,809 | 1,387,304 | 1,158,537 | 905,885 | 6,307,731 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | 123,566,649 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2020 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2020 |
(iii) Distributable Amount for 2020 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2020 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2020: | ||||
| a From 2015....... | ||||
| b From 2016....... | ||||
| c From 2017....... | ||||
| d From 2018....... | ||||
| e From 2019....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2020 distributable amount | ||||
|
i
Carryover from 2015 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2020 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2020 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2020, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2020. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2021. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2016..... | ||||
| b Excess from 2017..... | ||||
| c Excess from 2018..... | ||||
| d Excess from 2019..... | ||||
| e Excess from 2020..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED): | THE GAPS IN KNOWLEDGE WE AIM TO BRIDGE ARE TO DEFINE AND CHARACTERIZE NOVEL PNEUMOCOCCAL ANTIGENIC PROTEINS AND POLYELECTROLYTE ADJUVANTS FORMULATIONS THAT WILL INITIATE ADAPTIVE IMMUNE RESPONSES AND LEAD TO PROTECTION AGAINST DISEASE IN A SEROTYPE INDEPENDENT MANNER. THE PROPOSED WORK IS SIGNIFICANT DUE TO THE HIGH INCIDENCE SEROTYPE REPLACEMENT THAT CURRENT POLYSACCHARIDE-BASED VACCINES ARE PRONE TO, WHICH LEADS TO INCREASE SUSCEPTIBILITY OF CHILDREN AND THE ELDERLY TO SPN CARRIAGE AND SEVERE INFECTIONS (E.G., PNEUMONIA, BACTEREMIA, AND MENINGITIS); AND INNOVATIVE SINCE IT WILL USE NOVEL FORMULATIONS OF ANTIGENIC AND CONSERVED PNEUMOCOCCAL PROTEINS TO INDUCE POTENT ADAPTIVE IMMUNE RESPONSES, THAT WILL NOT BE SEROTYPE DEPENDENT. FUNDED THROUGH THE NATIONAL INSTITUTE OF ALLERGY AND IMMUNOLOGY (NIAID/NIH) INTERPLAY BETWEEN THE HEAT SHOCK RESPONSE AND HISTIDINE KINASE PATHWAYS IN THE THERMALLY DIMORPHIC FUNGAL PATHOGEN HISTOPLASMA CAPSULATUM. HISTOPLASMA CAPSULATUM IS ONE OF SEVERAL SYSTEMIC DIMORPHIC FUNGAL PATHOGENS THAT SWITCH THEIR GROWTH PROGRAM FROM AN INFECTIOUS MOLD FORM IN THE SOIL TO A PATHOGENIC YEAST FORM IN MAMMALIAN HOSTS. H. CAPSULATUM CAUSES UP TO 25,000 LIFE-THREATENING INFECTIONS PER YEAR IN THE U.S. ALONE WITH UP TO 50% MORTALITY RATE AND IS THE MOST COMMON CAUSE OF FUNGAL RESPIRATORY INFECTIONS IN HEALTHY HOSTS. INFECTION OCCURS WHEN THE SOIL IS DISRUPTED, FACILITATING DISPERSION OF HYPHAL FRAGMENTS OR SPORES THAT ARE INHALED BY HUMANS. SPORES AND HYPHAL FRAGMENTS ARE THE PRIMARY INFECTIOUS AGENTS; HOWEVER, ONCE INTRODUCED INTO THE HOST, THE PATHOGEN CONVERTS TO A BUDDING-YEAST FORM, WHICH SURVIVES AND REPLICATES WITHIN HOST MACROPHAGES. HUMAN BODY TEMPERATURE IS THE PRIMARY SIGNAL FOR CONVERSION FROM AN INFECTIOUS TO A PARASITIC FORM IN HISTOPLASMA. DESPITE ITS IMPORTANCE TO HUMAN HEALTH, VERY LITTLE IS KNOWN ABOUT HOW H. CAPSULATUM SENSES AND RESPONDS TO HUMAN BODY TEMPERATURE. THE JCVI IN OUR FUNDED NIH R01 PROJECT, HAS PROPOSED TO BUILD UPON ITS PREVIOUS FINDINGS AND FULLY CHARACTERIZE THE INVOLVEMENT OF THE HEAT SHOCK RESPONSE AND HISTIDINE KINASE PATHWAYS IN REGULATING CELL MORPHOLOGY AND VIRULENCE TRAITS IN H. CAPSULATUM IN RESPONSE TO HOST TEMPERATURE. JCVI HAS BEEN WORKING ON IMPROVING H. CAPSULATUM GENOME ASSEMBLY. TO THIS END, IT USED LONG-READ SEQUENCING TECHNOLOGY AND SUCCESSFULLY COMPLETED CHROMOSOMAL LEVEL ASSEMBLIES OF FIVE COMMONLY USED HISTOPLASMA STRAINS, WHICH HAVE SIX OR SEVEN CHROMOSOMES. JCVI DESCRIBED ITS FINDINGS IN A MANUSCRIPT THAT IS CURRENTLY UNDER REVISION AT THE MBIO JOURNAL. JCVI WILL BE UTILIZING ITS NEW ASSEMBLIES AND ANNOTATIONS IN THE TRANSCRIPTOME STUDIES THAT IT HAS BEEN PERFORMING WITHIN THE SCOPE OF OUR FUNDED PROJECT. RESULTS OF THIS PROJECT WILL PROVIDE FUNDAMENTAL INFORMATION ON HOW CELLS SENSE TEMPERATURE AND TURN ON THE APPROPRIATE VIRULENCE PATHWAYS IN THE HOST. ULTIMATELY, THE INFORMATION OBTAINED FROM THIS PROJECT CAN BE USED TO DEVELOP THERAPEUTICS FOR H. CAPSULATUM INFECTIONS AND HELP PREVENT OTHER DIMORPHIC FUNGAL INFECTIONS. GREATER THAN 10% OF HIV PATIENTS INJECT ILLICIT DRUGS AND WITH THE RISING OPIOID CRISIS AND THE INCREASED RISK OF HIV IN THESE PATIENTS, IT IS CRITICAL WE UNDERSTAND HOW SUBSTANCE USE INFLUENCES THE SPREAD AND COURSE OF HIV INFECTION AND DISEASE. FUNDED BY THE NATIONAL INSTITUTE OF DRUG ABUSE (NIDA/NIH) AND IN COLLABORATION WITH BOSTON UNIVERSITY, THIS STUDY SPECIFICALLY ADDRESSES HOW OPIOID ABUSE ALTERS THE IMMUNE RESPONSE IN HIV PATIENTS AND WITH THIS CAN DIRECTLY CONTRIBUTE TO HIDDEN RESERVOIRS OF HIV. SUCCESSFUL COMPLETION OF THESE STUDIES WILL PROVIDE INSIGHTS INTO POTENTIAL STRATEGIES FOR TREATING HIV IN THIS GROWING POPULATION OF HIV PATIENTS. OUR CENTRAL HYPOTHESIS IS THAT OPIOID MISUSE EXACERBATES HIV PATHOGENESIS AND THE ESTABLISHMENT OF HIV LATENCY BY DYSREGULATING THE HOST IMMUNE RESPONSE. OUR OVERALL OBJECTIVE IS TO EXPLOIT TRANSCRIPTOMIC INFORMATION FROM PATIENT SAMPLES TO CHARACTERIZE THE EFFECTS OF OPIOID USE DISORDER ON HOST IMMUNE FUNCTION, HIV REPLICATION, AND HIV LATENCY. WE WILL CHARACTERIZE SINGLE CELL GENE EXPRESSION AND IDENTIFY DYSREGULATED GENE REGULATORY NETWORKS IN IMMUNE CELLS ASSOCIATED WITH OPIOID MISUSE IN PLWH. WE WILL ALSO PERFORM COMPUTATIONAL ANALYSIS TO IDENTIFY IMMUNE CELL GENE REGULATORY NETWORKS ALTERED BY OPIOID MISUSE AND WE WILL COMBINE SINGLE CELL RNA-SEQ AND FLUORESCENT IN SITU HYBRIDIZATION FLOW CYTOMETRY (FLOW-FISH) TO CHARACTERIZE THE TRANSCRIPTOME IN CELL MODELS OF LATENT HIV INFECTION. SUCCESSFUL COMPLETION OF THESE AIMS WILL HAVE SIGNIFICANT RESEARCH AND CLINICAL IMPACT BY: 1) ELUCIDATING HOW OPIOID MISUSE ALTERS HIV PATHOGENESIS; 2) PRODUCING NOVEL TOOLS FOR CHARACTERIZING HIV LATENCY; AND 3) DISCOVERING CANDIDATE MOLECULES TO REGULATE HIV EXPRESSION IN THE CONTEXT OF OPIOID MISUSE. SEVERAL ADDITIONAL DHHS GRANTS AT JCVI ARE RELATED TO HUMAN MICROBIOME STUDIES. THE MICROBIOME IS THE COLLECTION OF MICROBES THAT LIVE IN AND ON THE HUMAN BODY; THESE SPECIES HAVE RECEIVED CONSIDERABLE ATTENTION IN RECENT YEARS BECAUSE A NEW APPRECIATION OF THE COMPLEX ROLES THAT THEY PLAY IN HEALTH AND DISEASE. SOME OF THESE STUDIES ARE AIMED AT BASIC CHARACTERIZATION OF THE COMPOSITION AND ACTIVITY OF THE MICROBIOME, WHILE OTHERS SEEK TO UNDERSTAND THE CONTRIBUTION OF THE MICROBIOME TO THE DEVELOPMENT OF VARIOUS DISEASES INCLUDING ALCOHOLIC HEPATITIS, TYPE 1 DIABETES, DENTAL CARIES, DIARRHEA, AND ESOPHAGEAL CANCER, AMONG OTHERS. THE INSTITUTE IS AN ACTIVE PARTICIPATANT IN THE H3AFRICA PROGRAM VIA A COLLABORATION WITH THE UNIVERSITY OF CAPE TOWN, SOUTH AFRICA, TRAINING COLLABORATORS IN HUMAN MICROBIOME ANALYSIS. THE PROGRAM IS SPONSORED BY THE NIH COMMON FUND TO BRING TECHNOLOGICAL RESOURCES AND TRAINING IN A CAPITAL INVESTMENT-INTENSIVE FIELD (GENOMICS) TO THE AFRICAN CONTINENT VIA COLLABORATIONS WITH US SCIENTISTS WITH EXPERTISE IN THIS FIELD. |
| FORM 990, PART VI, SECTION A, LINE 2 | BOARD MEMBERS HEATHER KOWALSKI AND J. CRAIG VENTER HAVE A FAMILY RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 IS REVIEWED BY MANAGEMENT. A COMPLETE COPY OF THE FORM 990 AND SUPPORTING SCHEDULES WAS PROVIDED TO THE FULL BOARD FOR REVIEW PRIOR TO BEING FILED. |
| FORM 990, PART VI, SECTION B, LINE 12C | JCVI MONITORS COMPLIANCE OF ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL SOLICITATION OF CONFLICT OF INTEREST STATEMENTS FROM TRUSTEES, OFFICERS, AND EMPLOYEES. IF A PERSON HAS A CONFLICT WITH RESPECT TO A TRANSACTION, SUCH PERSON IS NOT ALLOWED TO VOTE. |
| FORM 990, PART VI, SECTION B, LINE 15 | JCVI USES AN OUTSIDE COMPENSATION CONSULTANT, TO PROVIDE A LIST OF COMPARABLE SALARIES FOR THE CEO AND OFFICERS THESE ARE REVIEWED BY THE JCVI COMPENSATION COMMITTEE AND CEO BEFORE A FINAL DETERMINATION IS MADE. THIS PROCESS WAS DOCUMENTED AND LAST DONE IN OCTOBER 2018. |
| FORM 990, PART VI, SECTION C, LINE 19 | THE ORGANIZATION'S FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, AND CONFLICT OF INTEREST POLICY ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. |
| FORM 990, PART XI, LINE 9: | K-1 PASSTHROUGH -15,294. |
| Software ID: | |
| Software Version: |